SELF-REPORT CREDIT FORM

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Johns Hopkins University School of Medicine and the National Institutes of Health. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:
The Johns Hopkins University School of Medicine designates this live activity for 1 credit per session for a maximum of 44 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Clinical Center Grand Rounds
Lipsett Amphitheater
12 Noon – 1 p.m.
October 24, 2012

The Genetic Basis of Kidney Cancer: A Metabolic Disease
W. Marston Linehan, M.D., Chief, Urologic Oncology Branch, Center for Cancer Research, NCI

From Symptoms to Biomarkers: Modern Myeloma Treatment Strategies
Ola Landgren, M.D., Ph.D., Senior Investigator and Chief, Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, NCI

NOTE: To receive credit for attendance, this form must be returned to the Office of Clinical Research Training and Medical Education by 4 pm on the day of the lecture. Please fax forms to 301-435-5275. For CC Grand Rounds CME inquiries, contact Daniel McAnally at 301-496-9425 or daniel.mcanally@nih.gov

<table>
<thead>
<tr>
<th>Date(s)</th>
<th>Maximum Approved Hours per session/per week</th>
<th>Earned Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>October 24, 2012</td>
<td>1 hour per session/per week</td>
<td>1.0*</td>
</tr>
</tbody>
</table>

Please Print Clearly

Please check one: _____Physician _____Non-Physician

NAME - LAST                       FIRST               MI PROFESSIONAL DEGREE

NIH Badge Number (if NIH Employee)

PHONE                      EMAIL                      ORGANIZATION      INSTITUTE/CENTER      DEPT/BRANCH

ADDRESS                      CITY                      STATE            ZIP + 4

SIGNATURE REQUIRED for ALL ATTENDEES:
I attest that the above number credit hour(s) is correct.

X ________________________________  __________________________
Signature of Attendee             Date

*These hours will be verified by the Office of Continuing Medical Education (OCME) and recorded on your official Transcript.
FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES

Clinical Center Grand Rounds
Lipsett Amphitheater
Bethesda, Maryland
October 24, 2012

As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Speakers are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:

SPEAKERS NAME AND LECTURE TITLES

W. Marston Linehan, M.D.
The Genetic Basis of Kidney Cancer: A Metabolic Disease

Ola Landgren, M.D., Ph.D.
From Symptoms to Biomarkers: Modern Myeloma Treatment Strategies

No speaker has indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentations.

No planner has indicated that they have any financial interests or relationships with a commercial entity.

Note: Grants to investigators at the Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

OFF-LABEL PRODUCT DISCUSSION

The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products:

<table>
<thead>
<tr>
<th>Name</th>
<th>Product</th>
</tr>
</thead>
<tbody>
<tr>
<td>W. Marston Linehan, M.D.</td>
<td>Tarceva</td>
</tr>
</tbody>
</table>

The Genetic Basis of Kidney Cancer: A Metabolic Disease
Please complete the Continuing Medical Education Questionnaire. To indicate your answers, use the rating scale that is shown by circling the number that represents your answer.

Scale:
1 - None or Not at all  2 - Very little  3 - Moderately  4 - Considerably  5 - Completely  N/A - Not applicable

Speaker: W. Marston Linehan, M.D.

Objective: Discuss, describe, and identify the genetic basis of kidney cancer.

A. Rating of Objectives and Activity

1. Please rate the attainment of objectives:
   a. Define options and alternatives that will guide clinical practice
      1  2  3  4  5  N/A
   b. Evaluate practical information about clinical research principles based on state-of-the-art information about scientific discovery and clinical advances
      1  2  3  4  5  N/A
   c. Analyze information and opportunities to increase and improve collaboration between investigators
      1  2  3  4  5  N/A

2. The overall quality of the instructional process was an asset to the activity:
   1  2  3  4  5  N/A

3. To what extent did participation in this activity enhance your professional effectiveness?
   1  2  3  4  5  N/A

4. Will you change your practice in any way as a result of attending this activity?
   1  2  3  4  5  N/A

5. Did you perceive any commercial bias?
   Use the following criteria to judge?
   a) The content presented was balanced, evidence-based, demonstrated scientific rigor, and was without commercial bias. Use the following criteria to judge?
      1  2  3  4  5  6  N/A
      No  Yes
      If no, please specify: ________________________________
   b) I was informed about the existence and resolution of relevant financial relationships/conflicts of interests of planners and presenters prior to the presentation.
      1  2  3  4  5  N/A
      No  Yes
      If no, please specify: ________________________________
   c) Speakers who discussed off-label, investigational, or alternative uses of products, devices, or techniques disclosed this in their presentation.
      1  2  3  4  5  N/A
      No  Yes
      If no, please specify: ________________________________

B. Comments:

1. What comments or suggestions do you have for the faculty presenter(s)?
   __________________________________________

2. Are there any other speakers or new topics you would like to have covered in this or a related activity?
   __________________________________________

3. Do you have additional comments to enhance the utility or impact of the activity?
   __________________________________________

4. May we contact you in several week’s time with a very brief survey to assess the usefulness of this CME activity?  Yes  No  If yes, please provide your email: ________________________________
Please complete the Continuing Medical Education Questionnaire. To indicate your answers, use the rating scale that is shown by circling the number that represents your answer.

Scale:
1 - None or Not at all  2 - Very little  3 - Moderately  4 - Considerably  5 - Completely  N/A - Not applicable

Objective: To discuss molecular subtypes of myeloma and its precursor disease and functional imaging in myeloma. Discuss strategies for early intervention ("early myeloma").

A. Rating of Objectives and Activity
5. Please rate the attainment of objectives:
   a. Define options and alternatives that will guide clinical practice 1 2 3 4 5 N/A
   b. Evaluate practical information about clinical research principles based on state-of-the-art information about scientific discovery and clinical advances 1 2 3 4 5 N/A
   c. Analyze information and opportunities to increase and improve collaboration between investigators 1 2 3 4 5 N/A

6. The overall quality of the instructional process was an asset to the activity: 1 2 3 4 5 N/A

7. To what extent did participation in this activity enhance your professional effectiveness? 1 2 3 4 5 N/A

4. Will you change your practice in any way as a result of attending this activity? 1 2 3 4 5 N/A

5. Did you perceive any commercial bias? Use the following criteria to judge:
   b) The content presented was balanced, evidence-based, demonstrated scientific rigor, and was without commercial bias. If no, please specify: ___________________________________________ No Yes
   b) I was informed about the existence and resolution of relevant financial relationships/conflicts of interests of planners and presenters prior to the presentation. If no, please specify: ____________________________ No Yes
   c) Speakers who discussed off-label, investigational, or alternative uses of products, devices, or techniques disclosed this in their presentation. If no, please specify: ______________________________ No Yes

B. Comments:
1. What comments or suggestions do you have for the faculty presenter(s)?
   __________________________________________________________________________

2. Are there any other speakers or new topics you would like to have covered in this or a related activity?
   __________________________________________________________________________

3. Do you have additional comments to enhance the utility or impact of the activity?
   __________________________________________________________________________

8. May we contact you in several week’s time with a very brief survey to assess the usefulness of this CME activity? Yes No If yes, please provide your email: ________________________________